Preview

Эндокринная хирургия

Расширенный поиск

Актуальность и перспективные направления изучения проблемы субклинического синдрома Кушинга.

https://doi.org/10.14341/serg2016113-22

Полный текст:

Аннотация

Для цитирования:


Кузнецов Н.С., Латкина Н.В., Каминарская Ю.А. Актуальность и перспективные направления изучения проблемы субклинического синдрома Кушинга. Эндокринная хирургия. 2016;10(1):13-22. https://doi.org/10.14341/serg2016113-22

For citation:


Kuznetsov N.S., Latkina N.V., Kaminarskaya Yu.A. Relevance and perspective concept of investigation of subclinical Cushing syndrome. Endocrine Surgery. 2016;10(1):13-22. (In Russ.) https://doi.org/10.14341/serg2016113-22

Список литературы

1. Terzolo M, Stigliano A, Chiodini I, et al. AME Position Statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-870. doi: 10.1530/eje-10-1147.

2. Young WF. The Incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. doi: 10.1056/NEJMcp065470.

3. Mantero F, Arnaldi G. Management approaches to adrenal incidentalomas. Endocrinol Metab Clin North Am. 2000;29(1):107-125. doi: 10.1016/s0889-8529(05)70119-5.

4. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab. 2008;93(9):3266-3281. doi: 10.1210/jc.2008-0104.

5. Terzolo M, Bovio S, Pia A, et al. Subclinical Cushing's syndrome. Arq Bras Endocrinol Metabol. 2007;51(8):1272-1279.

6. Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am. 2000;29(1):43-56. doi: 10.1016/s0889-8529(05)70115-8.

7. Beierwaltes WH, Sturman MF, Ryo U, Ice RD. Imaging functional nodules of the adrenal glands with 131-I-19-iodocholesterol. J Nucl Med. 1974;15(4):246-251.

8. Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab. 2010;95(9):4106-4113. doi: 10.1210/jc.2010-0457.

9. Terzolo M. Adrenal incidentaloma: A new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3): 998-1003. doi: 10.1210/jcem.87.3.8277.

10. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocr Metab. 2010;95(6):2736-2745. doi: 10.1210/jc.2009-2387.

11. Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: An Italian Multicenter Study. J Clin Endocrinol Metab. 2009;94(9):3207-3214. doi: 10.1210/jc.2009-0468.

12. Toniato A, Merante-Boschin I, Opocher G, et al. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009;249(3):388-391. doi: 10.1097/SLA.0b013e31819a47d2.

13. Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: Clinical, biochemical and surgical outcomes. Endocr J. 2003;50(4):399-408. doi: 10.1507/endocrj.50.399.

14. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev. 2004;25(2):309-340. doi: 10.1210/er.2002-0031.

15. Starker LF, Kunstman JW, Carling T. Subclinical Cushing syndrome. Surg Clin North Am. 2014;94(3):657-668. doi: 10.1016/j.suc.2014.02.008.

16. Reimondo G, Allasino B, Bovio S, et al. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas. J Endocrinol Invest. 2011;34(1):e1-5. doi: 10.3275/7167.

17. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma“). Ann Intern Med. 2003;138(5):424-429.

18. Zeiger MA, Thompson GB, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract. 2009;15(5):450-453. doi: 10.4158/EP.15.5.450.

19. Read GF, Walker RF, Wilson DW, Griffiths K. Steroid analysis in saliva for the assessment of endocrine function. Ann N Y Acad Sci. 1990;595(1 Steroid Forma):260-274.

20. doi: 10.1111/j.1749-6632.1990.tb34300.x.

21. Garde AH, Hansen ÅM. Longterm stability of salivary cortisol. Scand J Clin Lab Invest. 2009;65(5):433-436. doi: 10.1080/00365510510025773.

22. Nunes M-L, Vattaut S, Corcuff J-B, et al. Late-night salivary cortisol for diagnosis of overt and subclinical Cushing’s syndrome in hospitalized and ambulatory patients. J Clin Endocr Metab. 2009;94(2):456-462. doi: 10.1210/jc.2008-1542.

23. Mengden T, Hubmann P, Muller J, et al. Urinary free cortisol versus 17-hydroxycorticosteroids a comparative study of their diagnostic value in Cushing's syndrome. The Clinical Investigator. 1992;70(7). doi: 10.1007/bf00184788.

24. Carroll BJ, Curtis GC, Davies BM, et al. Urinary free cortisol excretion in depression. Psychol Med. 1976;6(1):43-50.

25. Duclos M, Corcuff JB, Etcheverry N, et al. Abdominal obesity increases overnight cortisol excretion. J Endocrinol Invest. 1999;22(6):465-471. doi: 10.1007/BF03343591.

26. Mericq MV. High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab. 1998;83(2):682-684. doi: 10.1210/jcem.83.2.4555.

27. Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol. 2007;157(6): 725-731. doi: 10.1530/eje-07-0424.

28. Eller-Vainicher C, Morelli V, Salcuni AS, et al. Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. Eur J Endocrinol. 2010;163(6):925-935. doi: 10.1530/eje-10-0602.

29. Valli N, Catargi B, Ronci N, et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol. 2001;144(4):401-408.

30. Tanabe A, Naruse M, Nishikawa T, et al. Autonomy of cortisol secretion in clinically silent adrenal incidentaloma. Horm Metab Res. 2001;33(7):444-450. doi: 10.1055/s-2001-16234.

31. Shiwa T, Oki K, Yamane K, et al. Significantly high level of late-night free cortisol to creatinine ratio in urine specimen in patients with subclinical Cushing's syndrome. Clin Endocrinol (Oxf). 2013;79(5):617-622. doi: 10.1111/cen.12197.

32. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34(2):423-439, x. doi: 10.1016/j.ecl.2005.01.008.

33. Masserini B, Morelli V, Bergamaschi S, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur J Endocrinol. 2009;160(1):87-92. doi: 10.1530/EJE-08-0485.

34. Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96(5):1223-1236. doi: 10.1210/jc.2010-2722.

35. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2006;29(5):471-482. doi: 10.1007/BF03344133.

36. Osella G, Terzolo M, Borretta G, et al. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J Clin Endocrinol Metab. 1994;79(6):1532-1539. doi: 10.1210/jcem.79.6.7989452.

37. Di Dalmazi G, Kisker C, Calebiro D, et al. Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab.2014;99(10):E2093-2100. doi: 10.1210/jc.2014-2152.

38. Beuschlein F, Fassnacht M, Assie G, et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med. 2014;370(11):1019-1028.

39. doi: 10.1056/NEJMoa1310359.

40. Cao Y, He M, Gao Z, et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. Science. 2014;344(6186):913-917. doi: 10.1126/science.1249480.

41. Thiel A, Reis AC, Haase M, et al. PRKACA mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center study of 60 cases. Eur J Endocrinol. 2015;172(6): 677-685. doi: 10.1530/EJE-14-1113.

42. Sato Y, Maekawa S, Ishii R, et al. Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science. 2014;344(6186):917-920. doi: 10.1126/science.1252328.

43. Goh G, Scholl UI, Healy JM, et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet. 2014;46(6):613-617. doi: 10.1038/ng.2956.

44. Cao C, Yang X, Li L, et al. Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas. Int J Urol. 2011;18(10):691-696. doi: 10.1111/j.1442-2042.2011.02836.x.

45. Mitsuhiro K, Masashi D, Takashi Y. Epigenetic controls of CYP11B2 and CYP11B1 gene in subclinical Cushing syndrome associated with overproduction of aldosterone. Endocr. Soc. 96th Annu. Meet. Expo, 2014.

46. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol. 1999;11(5):634-640. doi: 10.1016/S0955-0674(99)00026-5.

47. Crickard K, Ill CR, Jaffe RB. Control of proliferation of human fetal adrenal cells in vitro. J Clin Endocrinol Metab. 1981;53(4):790-796. doi: 10.1210/jcem-53-4-790.

48. Chamoux E, Narcy A, Lehoux JG, Gallo-Payet N. Fibronectin, laminin, and collagen IV interact with ACTH and angiotensin II to dictate specific cell behavior and secretion in human fetal adrenal cells in culture. Endocr Res.2002;28(4):637-640. doi: 10.1081/ERC-120016978.

49. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond). 1999;96(5):513-523. doi: 10.1042/CS19980388.

50. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39(2):81-93. doi: 10.1111/j.1365-2362.2008.02067.x.

51. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000;85(4):1440-1448. doi: 10.1210/jcem.85.4.6515.

52. Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87(11):4872-4878. doi: 10.1210/jc.2001-011766.

53. Morelli V, Masserini B, Salcuni AS, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf). 2010;73(2): 161-166. doi: 10.1111/j.1365-2265.2010.03794.x.

54. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-644. doi: 10.1210/jcem.85.2.6372.

55. Bernini GP, Moretti A, Oriandini C, et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer. 2005;92(6): 1104-1109. doi: 10.1038/sj.bjc.6602459.

56. Terzolo M, Bovio S, Pia A, et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol. 2005;153(2):307-315. doi: 10.1530/eje.1.01959.

57. Sereg M, Szappanos A, Toke J, et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol. 2009; 160(4):647-655. doi: 10.1530/EJE-08-0707.

58. Vassilatou E, Vryonidou A, Michalopoulou S, et al. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf). 2009;70(5):674-679. doi: 10.1111/j.1365-2265.2008.03492.x.

59. Giordano R, Marinazzo E, Berardelli R, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol. 2010;162(4):779-785. doi: 10.1530/EJE-09-0957.

60. Comlekci A, Yener S, Ertilav S, et al. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine. 2010;37(1):40-46. doi: 10.1007/s12020-009-9260-5.

61. Giordano R, Guaraldi F, Berardelli R, et al. Glucose metabolism in patients with subclinical Cushing's syndrome. Endocrine. 2012;41(3):415-423. doi: 10.1007/s12020-012-9628-9.

62. Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. The Lancet Diabetes & Endocrinology. 2014;2(5):396-405. doi: 10.1016/s2213-8587(13)70211-0.

63. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study.Eur J Endocrinol. 2012;166(4):669-677. doi: 10.1530/eje-11-1039.

64. Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: A multicenter longitudinal study. J Bone Miner Res. 2011;26(8):1816-1821. doi: 10.1002/jbmr.398.

65. Chiodini I. Bone loss rate in adrenal incidentalomas: A longitudinal study. J Clin Endocrinol Metab. 2001;86(11): 5337-5341. doi: 10.1210/jcem.86.11.8022.

66. Eller-Vainicher C, Morelli V, Ulivieri FM, et al. Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J Bone Miner Res. 2012;27(10):2223-2230.doi: 10.1002/jbmr.1648.

67. Lane NE, Yao W. Glucocorticoid-induced bone fragility. Ann N Y Acad Sci. 2010;1192(1):81-83. doi: 10.1111/j.1749-6632.2009.05228.x.

68. Midorikawa S, Sanada H, Hashimoto S, et al. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf). 2001;54(6):797-804. doi: 10.1046/j.1365-2265.2001.01274.x.

69. Mitchell IC, Auchus RJ, Juneja K, et al. “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery. 2007;142(6):900-905.e901. doi: 10.1016/j.surg.2007.10.001.

70. Bernini G, Moretti A, Iacconi P, et al. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol. 2003;148(2):213-219. doi: 10.1530/eje.0.1480213.

71. Calebiro D, Di Dalmazi G, Bathon K, et al. cAMP signaling in cortisol-producing adrenal adenoma. Eur J Endocrinol. 2015;173(4):M99-M106. doi: 10.1530/eje-15-0353.


Об авторах

Николай Сергеевич Кузнецов
ФГБУ “Эндокринологический научный центр” Минздрава России
Россия
д.м.н., заведующий отделом хирургии, Институт клинической эндокринологии
Конфликт интересов:

Конфликт интересов отсутствует



Нонна Вадимовна Латкина
ФГБУ “Эндокринологический научный центр” Минздрава России
Россия

к.м.н., старший научный сотрудник, отдел хирургии, Институт клинической эндокринологии


Конфликт интересов:

Конфликт интересов отсутствует



Юлия Андреевна Каминарская
ГАУЗ МО “Химкинская центральная клиническая больница”, Московская область
Россия
врач-эндокринолог
Конфликт интересов:

Конфликт интересов отсутствует



Рецензия

Для цитирования:


Кузнецов Н.С., Латкина Н.В., Каминарская Ю.А. Актуальность и перспективные направления изучения проблемы субклинического синдрома Кушинга. Эндокринная хирургия. 2016;10(1):13-22. https://doi.org/10.14341/serg2016113-22

For citation:


Kuznetsov N.S., Latkina N.V., Kaminarskaya Yu.A. Relevance and perspective concept of investigation of subclinical Cushing syndrome. Endocrine Surgery. 2016;10(1):13-22. (In Russ.) https://doi.org/10.14341/serg2016113-22

Просмотров: 2197


ISSN 2306-3513 (Print)
ISSN 2310-3965 (Online)